Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Claudia Rodriguez Capriles"'
1
Akademický článek
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Autor: Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger
Publikováno v: Dermatology and Therapy, Vol 13, Iss 7, Pp 1517-1534 (2023)
Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clini
Externí odkaz: https://doaj.org/article/f1994888427840c4b87a98813eff0651
Zobrazit plný text záznamu
2
Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis
Autor: Adelaide A, Hebert, Margaret A, Bobonich, Claudia, Rodriguez Capriles, Gaia, Gallo, Lingnan, Li, Najwa, Somani, Terri, Ridenour, Yan, Wang, Emily, Edson-Heredia, Emily M, Becker
Publikováno v: Pediatric Dermatology. 39:55-60
Information is limited on the relationship between skin clearance, resolution of challenging body areas, and improvement of patient-reported outcomes (PROs) in pediatric psoriasis. Ixekizumab, a high-affinity monoclonal antibody that selectively targ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c99349ee0be6fe2888d621287536be
https://doi.org/10.1111/pde.14892
Zobrazit plný text záznamu
3
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)
Autor: Andrew Blauvelt, Alexa B. Kimball, Matthias Augustin, Yukari Okubo, Michael M. Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober
Publikováno v: The British journal of dermatologyReferences. 187(6)
Summary Background Interleukin-23 inhibitors are effective and safe for treating moderate-to-severe plaque psoriasis. Objectives To evaluate the efficacy and safety of mirikizumab in adult patients with moderate-to-severe plaque psoriasis through 52
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7923bfc129a51514306353bde00c6a
https://pubmed.ncbi.nlm.nih.gov/36065496
Zobrazit plný text záznamu
4
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
Autor: Amy S. Paller, Kimberley Jackson, Marieke M B Seyger, Claudia Rodriguez Capriles, Perla Lansang, Kim A. Papp, Nieves Velez de Mendizabal, Laiyi Chua, Celine Pitou
Publikováno v: British Journal of Clinical Pharmacology, 88, 1074-1086
British Journal of Clinical Pharmacology, 88, 3, pp. 1074-1086
Contains fulltext : 248294.pdf (Publisher’s version ) (Open Access) AIMS: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A used in the treatment of adult and paediatric patients with moderate-to-severe psor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e731f2bb601ccea9fce16a6c24a136e
http://hdl.handle.net/2066/248294
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje